<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698813</url>
  </required_header>
  <id_info>
    <org_study_id>UCMSC-HA-1</org_study_id>
    <nct_id>NCT02698813</nct_id>
  </id_info>
  <brief_title>Safety Study of Filler Agent Composed of Umbilical Cord Mesenchymal Stem Cells and Hyaluronic Acid</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>South China Research Center for Stem Cell and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South China Research Center for Stem Cell and Regenerative Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to evaluate the safety and exploratory efficacy of the&#xD;
      injectable filler agent composed of umbilical cord mesenchymal stem cells and hyaluronic acid&#xD;
      for the improvement of wrinkles, acne, pitting scar and so on.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with non-serious and serious adverse events</measure>
    <time_frame>Change from baseline up to week 12 after injection.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle Severity Rating Scale (WSRS) Evaluation</measure>
    <time_frame>Change from baseline at week 2, 6 and 12.</time_frame>
    <description>An improvement was judged by the outcome of the preoperative grade minus the postoperative grade in accordance with the Wrinkle Severity Rating Scale (WSRS).The severity was measured using the Wrinkle Severity Rating Scale (WSRS), where 0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Extreme, which is an ordinal scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) Evaluation</measure>
    <time_frame>Change from baseline at week 2, 6 and 12.</time_frame>
    <description>An improvement was judged by the outcome of the preoperative grade minus the postoperative grade in accordance with the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Senescence Wrinkles, Acne, Pitting Scar</condition>
  <arm_group>
    <arm_group_label>UCMSCs-HA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: Transdermal injection of hyaluronic acid only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cells and hyaluronic acid</intervention_name>
    <arm_group_label>UCMSCs-HA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronic acid</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female over 18 years;&#xD;
&#xD;
          2. Have ability to understand and comply with the study requirements, and provide the&#xD;
             written informed consent prior to any procedures ;&#xD;
&#xD;
          3. Suitable for the medical history and physical examination like the following&#xD;
             preoperative laboratory tests results: complete blood count, coagulation,&#xD;
             biochemistry, electrocardiogram, hepatogram and Î²-human chorionic gonadotropin (hCG)&#xD;
             for women of childbearing age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to undergo surgery liposuction with Klein technique as those with&#xD;
             severe cardiovascular disease, severe coagulation disorders including thrombophilia&#xD;
             and pregnancy;&#xD;
&#xD;
          2. Have history or active dermal diseases, inflammation, or any related disease;&#xD;
&#xD;
          3. Had invasive aesthetic treatments or surgeries history 6 months before the treatments;&#xD;
&#xD;
          4. Had physical or chemical aesthetic treatments 1 months before the study starts;&#xD;
&#xD;
          5. Have a known history of allergic reactions like hypersensitivity to hyaluronic acid;&#xD;
&#xD;
          6. Patients with limited understanding of the procedure or have poor compliance with the&#xD;
             study or follow-up schedule;&#xD;
&#xD;
          7. Pregnant or lactating;&#xD;
&#xD;
          8. Use of drugs;&#xD;
&#xD;
          9. Patients with preoperative results considered inadequate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuetao Pei, M.D., Ph.D</last_name>
    <phone>8610-68164807</phone>
    <email>AMMS0906@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fang Fang, Ph.D</last_name>
    <phone>8620-89199011</phone>
    <email>fangfang@scrm.org.cn</email>
  </overall_contact_backup>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

